Conference Coverage

Stroke endovascular therapy: The more you do, the better you do

View on the News

Volume concerns shouldn’t limit access

The idea that when centers perform more of a procedure, such as endovascular thrombectomy for acute ischemic stroke, they more often do it better is intuitively plausible, which helps makes these findings believable. It’s also a relationship we’ve already seen for other types of endovascular therapies. What this study did not address were other factors beyond case volume also might also make important contributions to outcome, such as the speed of treatment delivery.

Dr. Bruce Ovbiagele, chief of staff, San Francisco V.A. Health Care System

Dr. Bruce Ovbiagele

It’s been only 4 years since endovascular thrombectomy became standard of care in early 2015 for treating selected patients with an acute ischemic stroke. Since then, the focus of stroke clinicians has largely been on increasing the number of locations where patients could receive this important treatment. There remains a shortage of endovascular availability in many rural U.S. regions. The precedent clearly exists from other types of endovascular interventions for professional societies to set volume minimums that can sometimes be a surrogate marker of a center having and maintaining an optimal level of competence. But I don’t believe that we currently have adequate availability of endovascular stroke therapy to take this step. If we set a volume minimum now, it could deny treatment access to a significant number of patients.

Volume thresholds for endovascular stroke programs will come eventually, but for the time being our focus should be on insuring wide access to endovascular treatment.

Bruce Ovbiagele, MD, a neurologist and chief of staff for the San Francisco Veteran Affairs Health Care System, made these comments in an interview. He reported no disclosures.


 

REPORTING FROM ISC 2019

– The well-documented link between higher procedure volumes and better procedure efficacy also applies to endovascular thrombectomy for acute ischemic stroke.

Centers that performed more endovascular stroke therapy (EST) procedures produced better outcomes for patients in analysis of data from two different U.S. sources: the National Inpatient Sample (NIS) and the state of Florida, Sunil A. Sheth, MD, said at the International Stroke Conference sponsored by the American Heart Association.

Dr. Sunil A. Sheth, University of Texas Health Sciebnces Center at Houston Mitchel L. Zoler/MDedge News

Dr. Sunil A. Sheth

The finding raises questions about how to best triage patients with an acute ischemic stroke, suggesting that, in at least some situations, patients might be better served being taken to a higher-volume center even if it’s not the closest, noted Dr. Sheth, The results also suggest that the findings in the trials proving the value of EST run primarily at large, tertiary care, referral centers might not be generalizable to all centers that start an endovascular program.

The study looked at data collected during 2006-2016 in Florida and during 2012-2016 in the NIS, and found that in both databases the rate of EST procedures performed showed steadily increasing use over time, with a sharp increase in the number of centers performing EST in 2015. Each of the two data sets also showed that better discharge outcomes occurred in patients treated at centers with the highest procedural volumes.

In the nationwide NIS data, for every 10 additional patients a center treated with EST annually, the incidence of a “good” hospital-discharge outcome (defined as either discharge home or to an acute rehabilitation hospital) rose by 30%, compared with lower-volume centers in a multivariate regression analysis, a statistically significant relationship, said Dr. Sheth, a neurologist at the University of Texas, Houston. This volume-outcome relationship held fairly constant through volumes up to about 50 EST cases annually. “The more the better,” he observed.

“The data suggest that EST outcomes are not always the same,” but right now most emergency medical service systems do not take EST case volume into account when deciding where to take an acute stroke patient, Dr. Sheth said in an interview. But he cautioned against an oversimplified focus on just EST case volume.

A link between volume and better outcomes “is easy to understand and not surprising. We see this relationship for a variety of procedures. The data suggest we need to consider procedure volumes. But volume is only part of makes for good outcomes; it’s not the only factor,” he stressed.

Dr. Sheth and his associates used data collected by the Florida Agency for Health Care Administration on 3,890 acute ischemic stroke patients treated with EST at 56 Florida hospitals and on 42,505 such patients in the NIS database treated at 2,260 U.S. hospitals. During the 11-year period for Florida data collection, the number of centers performing EST in the state rose steadily at an average rate of about four new centers per year. Although the number of EST procedures done also rose sharply, in general over time a higher percentage of patients underwent treatment at lower-volume centers. Similar patterns existed in the national data. The Florida data showed a statistically significant 10% improvement in good discharge outcomes for every 10 additional EST patients a center treated a year, consistent with the NIS data.

Concurrently with Dr. Sheth’s report, the results also appeared in an article published online (Stroke. 2019 Feb 6. doi: 10.1161/STROKEAHA.118.023967).

Dr. Sheth reported no disclosures.

SOURCE: Sheth SA et al. ISC 2019, Abstract 002.

Recommended Reading

Statins cut vascular events in elderly patients
MDedge Cardiology
Intensive insulin added no benefit for hyperglycemia after ischemic stroke
MDedge Cardiology
Cilostazol plus aspirin or clopidogrel reduces the risk of recurrent stroke
MDedge Cardiology
Most U.S. tPA-eligible stroke patients now get treated within an hour
MDedge Cardiology
Vaccination and antiviral treatment do not affect stroke risk following shingles
MDedge Cardiology
Deferoxamine does not improve 90-day outcomes after ICH
MDedge Cardiology
Minimally invasive ICH lysis safely helps when clot adequately shrinks
MDedge Cardiology
ICYMI: Andexanet alfa reduces anti–factor Xa activity from apixaban, rivaroxaban
MDedge Cardiology
Hormone therapy in transgender individuals may up risk of CV events
MDedge Cardiology
Noncardiac surgery has 7% covert stroke rate in elderly
MDedge Cardiology